Thermo Fisher Scientific to Acquire QIAGEN for Approximately $11.5 Billion

From Jike Pharmaceutical News

On March 3, Thermo Fisher Scientific Inc. (Thermo Fisher, a global leader in scientific services) and QIAGEN (a global provider of molecular diagnostics and sample preparation technologies) jointly announced that their boards of directors had unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. Thermo Fisher will commence a tender offer for all outstanding ordinary shares of QIAGEN. At current exchange rates, the transaction values QIAGEN at approximately $11.5 billion. The deal is expected to close in the first half of 2021.

This transaction is expected to expand both parties’ portfolios in the specialty diagnostics sector through attractive molecular diagnostic capabilities, including infectious disease testing. Thermo Fisher Scientific has already established leading specialty diagnostics capabilities, encompassing allergy and autoimmune, transplant diagnostics, and clinical oncology testing. QIAGEN possesses strong expertise in molecular diagnostics, with a portfolio focused on infectious diseases and other growth opportunities. The combined company will accelerate the development of higher-specificity, faster, and more comprehensive tests, thereby potentially improving patient outcomes and reducing care costs.

Marc N. Casper, Chairman, President and Chief Executive Officer of Thermo Fisher Scientific, stated: “We are pleased to integrate complementary product portfolios to advance our customers’ critical work from discovery to diagnostics. This acquisition is expected to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs.”

“QIAGEN’s vision is to improve lives through our unique Sample to Insight molecular testing solutions. The strategic partnership with Thermo Fisher Scientific will enable us to deliver breakthrough solutions to customers worldwide, advancing our understanding of life sciences and improving health outcomes,” said Thierry Bernard, Interim CEO and Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN.

Casper concluded, “We look forward to and welcome QIAGEN employees joining Thermo Fisher Scientific, and we will advance new opportunities in precision medicine through innovative molecular diagnostic technologies and improved life sciences workflows.”

Reference: [1] Thermo Fisher Scientific to Acquire QIAGEN N.V. Retrieved Mar 3th, from https://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-acquire-qiagen-nv-301015072.html

Original Title: Major News! Thermo Fisher Scientific Acquires QIAGEN, Valued at Approximately $11.5 Billion

▽Follow [WuXi AppTecDe】WeChat Official Account